Abstract
The myelodysplastic syndromes (MDS) are a group of disorders characterized by a defective haematopoiesis resulting in cytopenia, bleeding and a high rate of infection. Moreover, the syndrome carries an increased risk of the patient developing acute non-lymphoid leukaemia (ANLL). Primary and post therapy MDS are recognized; we will discuss only the primary MDS of unknown aetiology. The diagnosis of MDS is based on quantitative and qualitative changes in both peripheral blood and bone marrow.’ The French-American-British (FAB) Cooperative Group proposed arbitrary guidelines for separating overt leukaemia from relatively stable or slowly progressive conditions; later they extended the range of the myelodysplastic syndromes and defined 5 subgroups known as:
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
